Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant Sep 12, 2016
Cellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global Investment Conference Sep 6, 2016
UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results Aug 12, 2016
Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results Aug 11, 2016
Cellectar Biosciences to Host Conference Call on August 15 to Report Second Quarter 2016 Financial Results and Corporate Performance Aug 8, 2016
Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study Aug 3, 2016
Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations Jul 20, 2016
Cellectar Biosciences Announces Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer Jun 23, 2016
Cellectar Biosciences Announces Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel Jun 15, 2016